Considering some patient challenges with taking daily oral therapy

Individuals featured have been compensated by ViiV Healthcare.

Real CABENUVA patients

Patient Ambassador Jorge

Jorge

Wanted to move away from daily pills that could give away his HIV status

Age: 45   |   Works as a mental health clinician

Treatment journey

  • Diagnosed in 2001, he struggled with accepting his HIV status and worried about daily adherence
  • While virologically suppressed, Jorge was worried about remembering to take his daily 
HIV treatment
  • Switched to CABENUVA from BIKTARVY

Clinical profile

  • BMI: 23 kg/m2
  • Virologically suppressed
  • Highly engaged in care; consistently shows up for doctor appointments

Nonclinical considerations

  • Worried over remembering if he took his daily oral HIV medication
  • Does not want a daily reminder of his 
HIV status

See preference data from BEYOND

Patient Ambassador Miranda

MIRANDA

Wanted a treatment she didn’t have to worry about remembering to take daily

Age: 38   |   Works as a prevention navigator in healthcare

Treatment journey

  • Diagnosed in 2000, she was worried about others knowing her HIV status
  • Discussed CABENUVA with her doctor
  • Switched to CABENUVA from BIKTARVY

Clinical profile

  • BMI: 31 kg/m2
  • Virologically suppressed on BIKTARVY
  • Highly engaged in care; consistently shows up for doctor appointments

Nonclinical considerations

  • Struggled with disclosing her HIV status to those around her and constantly worried about remembering to take her daily pill
  • Is in love and happily married; prides herself on managing her family's busy schedule

See challenge data from SOLAR

Miranda's switch to CABENUVA

It starts with recognizing there are some patients who could benefit from a long-acting regimen

Patients entering SOLAR on BIKTARVY revealed challenges with taking continuing daily oral therapy at baseline

On Day 1, patients in SOLAR (N=670; mlTT-E) responded to 3 baseline questions about their previous experience on a daily oral therapy (exploratory endpoint).1

Patient Ambassador Miranda on long-acting CABENUVA

47%

of patients in SOLAR reported experiencing at least one of the following challenges always or often*:

  • Worried about people unintentionally discovering their HIV status
  • Worried about forgetting to take their HIV medication
  • Felt that taking their HIV medication was an uncomfortable reminder of their HIV status

These results are descriptive in nature and should not be used to infer clinical significance.

  1. Patients were asked each of the following questions: “How often are you worried people may unintentionally discover your HIV status because of your current HIV treatment?”; “How often are you worried about forgetting to take your HIV medication?”; and “How often is taking your HIV medication an uncomfortable reminder of your HIV status?” Patients who responded “always” or “often” to any of these questions were counted one time for the endpoints above.1

  • SOLAR Study Design

    SOLAR is the first head-to-head switch study comparing every-2-month CABENUVA with continuing daily oral BIKTARVY1,2

    A large phase 3b, open-label, noninferiority study of virologically suppressed* adults (≥18 years) with HIV-1

    CABENUVA vs BIKTARVY SOLAR study with virologically suppressed patients
    Primary endpoint, exclusion criteria, and key baseline characteristics for patients in the SOLAR study
    • Efficacy analyses, baseline questionnaire, and preference calculation were based on the mITT-E (N=670) population. After consultation with a blinded external expert, 11 participants at a single study site were excluded from the ITT-E population due to critical findings related to significant and persistent noncompliance to protocol requirements
    • Safety analyses were based on ITT-E (N=681) population
    1. Suppression defined as plasma HIV-1 RNA <50 copies/mL. A single prior INSTI-based regimen was allowed for reasons other than treatment failure.1
    2. 39% (n=173) started with oral lead-in (OLI) and 61% (n=274) of patients in the CABENUVA arm started with injections (SWI) without OLI. OLI regimen consisted of 30-mg cabotegravir and 25-mg rilpivirine once daily given for 1 month; on last day of the OLI period, patients received 2 sets of initiation CABENUVA injections 1 month apart followed by every-2-month injections thereafter.1
    3. Month 12 (OLI and BIKTARVY) and Month 11 (SWI).1
    Primary endpoint, secondary efficacy endpoint, and exclusion criteria for SOLAR study patients

Each patient’s story offers a different perspective

Meet more CABENUVA patients

BMI=body mass index.

References:

  1. Ramgopal MN, Castagna A, Cazanave C, et al. Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial. Lancet HIV. 2023;10(9):E566-E577. doi.org/10.1016/S2352-3018(23)00136-4
  2. Data on file. ViiV Healthcare group of companies. Durham, NC.

PMUS-CBRWCNT240092